US.INCY · Incyte

{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.6,
      "details": {
        "atrPct": 2.6989572822065253,
        "turnoverUsdM": 508.89506952,
        "liquidityPoints": 0.6,
        "volatilityPoints": 1
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.INCY",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 112.5008,
      "strength_details": {
        "ma_score": 1.5,
        "atr_score": 2,
        "rsi_score": 2,
        "macd_score": 1.5,
        "volume_score": 3
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1.3,
      "stop_loss_percent": 5.4,
      "take_profit_price": 126.9493,
      "target_multiplier": 1.9,
      "technical_strength": 1.98,
      "take_profit_percent": 6.8
    },
    "positionPoints": 1.6,
    "stopLossPoints": 1.8,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2597457627118644,
    "stopLossPercent": 5.397914564413051,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 79.5,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 62.5,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 17
  },
  "market": {
    "ma20": 116.253,
    "ma50": 106.8182,
    "close": 118.92,
    "prevClose": 117.67,
    "avgVolume20": 1703730,
    "volumeRatio": 2.51,
    "changePercent": 1.06
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 17,
    "details": {
      "ret_5d": 0.02827496757457837,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 17,
      "vcp_bonus": 2,
      "vol_ratio": 2.5479491042030116,
      "ret_points": 4,
      "vol_points": 8,
      "range_ratio": 0.9532415158546208,
      "volat_points": 0,
      "day_range_pct": 0.026530440632357776,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 3,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 79.5,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 5,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 100,
        "contribution": 5
      },
      {
        "raw": 14.8,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 74,
        "contribution": 14.8
      },
      {
        "raw": 4.6,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 30.67,
        "contribution": 4.6
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 6.8,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 68,
        "contribution": 6.8
      },
      {
        "raw": 23.3,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 77.67,
        "contribution": 23.3
      },
      {
        "raw": 6,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 60,
        "contribution": 6
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "incomplete",
  "standard110": {
    "rating": "觀望",
    "result": 62.5,
    "details": [
      "基本面分析總分: 5/5分",
      "資金流分析總分: 14.8/20分",
      "市場環境分析總分: 4.6/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 6.8/10分",
      "技術信號分析總分: 23.3/30分",
      "情緒分析: 6/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 5,
      "資金流": 14.8,
      "市場環境": 4.6,
      "情緒分析": 6,
      "技術信號": 23.3,
      "風險管理": 6.8
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "優秀",
        "items": {
          "pbPoints": 0.2,
          "pePoints": 0.5,
          "epsPoints": 0.75,
          "roePoints": 0.75,
          "debtPoints": 0.5,
          "marginPoints": 0.75,
          "turnoverUsdM": 508.89506952,
          "volumePoints": 0.5,
          "revenuePoints": 0.75,
          "dividendPoints": 0,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "良好",
        "items": {
          "cmfPoints": 1.6,
          "mfiPoints": 3.2,
          "obvPoints": 4,
          "vwapPoints": 4,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.INCY",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "較差",
        "items": {
          "vix": {
            "score": 0,
            "details": {
              "source": "twelvedata+fred",
              "missing": true,
              "vixClose": null
            }
          },
          "trend": {
            "score": 0.8,
            "details": {
              "qqq": {
                "ma20": 710.4899991500001,
                "ma50": 717.6342017599999,
                "name": "QQQ",
                "close": 682.059998,
                "points": 0.4
              },
              "spy": {
                "ma20": 746.6545068500001,
                "ma50": 745.00220184,
                "name": "SPY",
                "close": 739.02002,
                "points": 0.4
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 2.6989572822065253,
          "atrPoints": 3,
          "cciPoints": 0.8,
          "vixPoints": 0,
          "marketTrendPoints": 0.8
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "一般",
        "items": {
          "sentiment": {
            "score": 6,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 0,
              "positiveHits": 4,
              "sentimentScoreRaw": 1.2
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 141031220,
                "url": "https://finnhub.io/api/news?id=2d9b5d3986d187fb5197c5ef9b0edab80e70e9a9efcc6abde9508b72f0a279da",
                "image": "https://www.chartmill.com/images/uploads/CM_Breakout_Stocks_Small_free_bb09e243c7.webp",
                "source": "ChartMill",
                "related": "INCY",
                "summary": "INCY stock shows a perfect technical breakout setup with a 10/10 Technical Rating and 9/10 Setup Quality, featuring a bull flag pattern and strong momentum.",
                "category": "company",
                "datetime": 1785140441,
                "headline": "INCYTE CORP (NASDAQ:INCY) Exhibits Perfect Technical Breakout Setup with Strong Ratings"
              },
              {
                "id": 141030717,
                "url": "https://finnhub.io/api/news?id=ad4f54ff1118d2b454e581ed1dfde278d76cb2e6b8f5c0deb0f11f897d8b3228",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) will be reporting results this Tuesday before the bell. Here’s what to look for.",
                "category": "company",
                "datetime": 1785126542,
                "headline": "What To Expect From Incyte’s (INCY) Q2 Earnings"
              },
              {
                "id": 141021094,
                "url": "https://finnhub.io/api/news?id=3dc13cfc64224bb859f64f02def1e1e27d7a4e954ab5830cfdac7e3136c8c299",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte (NasdaqGS:INCY) reported full safety and efficacy results from its Phase 1/2 study of latarcibart, a once monthly subcutaneous therapy for von Willebrand disease. The company announced the acquisition of VGA039 (latarcibart) through the purchase of Vega Therapeutics to support further development. Latarcibart carries breakthrough, fast track, orphan drug, and rare pediatric disease designations. For investors tracking Incyte, this update sits at the intersection of rare disease drug...",
                "category": "company",
                "datetime": 1785028292,
                "headline": "Incyte (INCY) Reports Full Latarcibart Data And Buys Vega Therapeutics"
              },
              {
                "id": 141004058,
                "url": "https://finnhub.io/api/news?id=c6d0f91d2a89e21ca5c3f4abc044cb229a668a9fb38d1b68174b1f2d89a4b18a",
                "image": "https://www.chartmill.com/images/uploads/HGM_Breakout_19d1a7df53.webp",
                "source": "ChartMill",
                "related": "INCY",
                "summary": "INCY stock shows strong earnings acceleration with 304% EPS growth and a perfect technical rating of 10, offering a defined breakout entry above $118.53 for momentum investors.",
                "category": "company",
                "datetime": 1784889636,
                "headline": "INCYTE CORP (NASDAQ:INCY) Screens as a High Growth Momentum Stock with a Breakout Setup"
              },
              {
                "id": 140971589,
                "url": "https://finnhub.io/api/news?id=6e9cb60560ec50a9dc2a5e4ff31cabd7f9a7b79b6c11da15cec0d4eda37c4146",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Halozyme grants ENHANZE rights to Incyte for developing subcutaneous cancer therapy formulations, aiming to improve treatment convenience for patients.",
                "category": "company",
                "datetime": 1784644680,
                "headline": "HALO Inks Deal With INCY to Support Cancer Therapy Development"
              },
              {
                "id": 140972028,
                "url": "https://finnhub.io/api/news?id=ea7c64df2412008d93ad36aeb06ea3400274c5b1bce9ff23162a508765035b15",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte (INCY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
                "category": "company",
                "datetime": 1784642419,
                "headline": "Incyte (INCY) Reports Next Week: Wall Street Expects Earnings Growth"
              },
              {
                "id": 140958478,
                "url": "https://finnhub.io/api/news?id=cc6ec253511baccbdfea5ad1f5f444625c032d12536f4b0d04339169e1be0d6d",
                "image": "https://www.chartmill.com/images/uploads/Undervalued_500_264px_webp_74997b3ff2.webp",
                "source": "ChartMill",
                "related": "INCY",
                "summary": "Incyte Corp (INCY) offers a compelling value opportunity with strong profitability, near-zero debt, and a P/E of 15.76—well below the biotech industry average of 36.43. Despite slowing growth forecasts, its low valuation provides a solid margin of safety.",
                "category": "company",
                "datetime": 1784546426,
                "headline": "Incyte Corp (NASDAQ:INCY) Shows Value Stock Strength With Strong Fundamentals and Low Valuation"
              },
              {
                "id": 140911616,
                "url": "https://finnhub.io/api/news?id=a21356dd71ba4a29f749ef6a9402b694ac4b5f7bec9fd511f75b6d42947c718e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 8.6% to $114.25 per share while the index has gained 8.2%.",
                "category": "company",
                "datetime": 1784133437,
                "headline": "Incyte (INCY): Buy, Sell, or Hold Post Q1 Earnings?"
              }
            ],
            "raw_source": [
              {
                "id": 141031220,
                "url": "https://finnhub.io/api/news?id=2d9b5d3986d187fb5197c5ef9b0edab80e70e9a9efcc6abde9508b72f0a279da",
                "image": "https://www.chartmill.com/images/uploads/CM_Breakout_Stocks_Small_free_bb09e243c7.webp",
                "source": "ChartMill",
                "related": "INCY",
                "summary": "INCY stock shows a perfect technical breakout setup with a 10/10 Technical Rating and 9/10 Setup Quality, featuring a bull flag pattern and strong momentum.",
                "category": "company",
                "datetime": 1785140441,
                "headline": "INCYTE CORP (NASDAQ:INCY) Exhibits Perfect Technical Breakout Setup with Strong Ratings"
              },
              {
                "id": 141030717,
                "url": "https://finnhub.io/api/news?id=ad4f54ff1118d2b454e581ed1dfde278d76cb2e6b8f5c0deb0f11f897d8b3228",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) will be reporting results this Tuesday before the bell. Here’s what to look for.",
                "category": "company",
                "datetime": 1785126542,
                "headline": "What To Expect From Incyte’s (INCY) Q2 Earnings"
              },
              {
                "id": 141021094,
                "url": "https://finnhub.io/api/news?id=3dc13cfc64224bb859f64f02def1e1e27d7a4e954ab5830cfdac7e3136c8c299",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte (NasdaqGS:INCY) reported full safety and efficacy results from its Phase 1/2 study of latarcibart, a once monthly subcutaneous therapy for von Willebrand disease. The company announced the acquisition of VGA039 (latarcibart) through the purchase of Vega Therapeutics to support further development. Latarcibart carries breakthrough, fast track, orphan drug, and rare pediatric disease designations. For investors tracking Incyte, this update sits at the intersection of rare disease drug...",
                "category": "company",
                "datetime": 1785028292,
                "headline": "Incyte (INCY) Reports Full Latarcibart Data And Buys Vega Therapeutics"
              },
              {
                "id": 141007726,
                "url": "https://finnhub.io/api/news?id=05aeb953d4a880fc4fda1e7fcea9049fded33c60c04eb95d11f61b77c46633f7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "INCY heads into Q2 earnings with strong Jakafi demand, Opzelura momentum and rising royalties, fueling expectations for an earnings beat.",
                "category": "company",
                "datetime": 1784903880,
                "headline": "Incyte Gears Up to Report Q2 Earnings: Is a Beat Around the Corner?"
              },
              {
                "id": 141004058,
                "url": "https://finnhub.io/api/news?id=c6d0f91d2a89e21ca5c3f4abc044cb229a668a9fb38d1b68174b1f2d89a4b18a",
                "image": "https://www.chartmill.com/images/uploads/HGM_Breakout_19d1a7df53.webp",
                "source": "ChartMill",
                "related": "INCY",
                "summary": "INCY stock shows strong earnings acceleration with 304% EPS growth and a perfect technical rating of 10, offering a defined breakout entry above $118.53 for momentum investors.",
                "category": "company",
                "datetime": 1784889636,
                "headline": "INCYTE CORP (NASDAQ:INCY) Screens as a High Growth Momentum Stock with a Breakout Setup"
              },
              {
                "id": 141008283,
                "url": "https://finnhub.io/api/news?id=a3c2f7a33f947eadc415691b2014909cd794a2fd6fde678f16f4a21b275753f3",
                "image": "",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "JP Morgan  analyst Jessica Fye   maintains Incyte (NASDAQ:INCY) with a Neutral and raises the price target from $105 to $110.",
                "category": "company",
                "datetime": 1784817699,
                "headline": "JP Morgan Maintains Neutral on Incyte, Raises Price Target to $110"
              },
              {
                "id": 141008284,
                "url": "https://finnhub.io/api/news?id=4fa3db6dad4d32f41a2fe234aa35c45d9af1dc13c079b1d15b07f323c67cd202",
                "image": "",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "Morgan Stanley  analyst Judah Frommer   maintains Incyte (NASDAQ:INCY) with a Equal-Weight and raises the price target from $103 to $104.",
                "category": "company",
                "datetime": 1784815340,
                "headline": "Morgan Stanley Maintains Equal-Weight on Incyte, Raises Price Target to $104"
              },
              {
                "id": 140983371,
                "url": "https://finnhub.io/api/news?id=246cd6e33abf5deef3bb65b29fdbc58a7be46dfa9b5832fd032d7466d9b44940",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "LENZ Therapeutics, Inc. (LENZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
                "category": "company",
                "datetime": 1784728830,
                "headline": "Earnings Preview: LENZ Therapeutics, Inc. (LENZ) Q2 Earnings Expected to Decline"
              },
              {
                "id": 140971589,
                "url": "https://finnhub.io/api/news?id=6e9cb60560ec50a9dc2a5e4ff31cabd7f9a7b79b6c11da15cec0d4eda37c4146",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Halozyme grants ENHANZE rights to Incyte for developing subcutaneous cancer therapy formulations, aiming to improve treatment convenience for patients.",
                "category": "company",
                "datetime": 1784644680,
                "headline": "HALO Inks Deal With INCY to Support Cancer Therapy Development"
              },
              {
                "id": 140972028,
                "url": "https://finnhub.io/api/news?id=ea7c64df2412008d93ad36aeb06ea3400274c5b1bce9ff23162a508765035b15",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte (INCY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
                "category": "company",
                "datetime": 1784642419,
                "headline": "Incyte (INCY) Reports Next Week: Wall Street Expects Earnings Growth"
              },
              {
                "id": 140972899,
                "url": "https://finnhub.io/api/news?id=b5039eeb51094b56bb15c6fbd0589d8bb8cc90e6bad42f0e7c7cf28242d94726",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1160060870/image_1160060870.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "INCY",
                "summary": "Baker Brothers’ Q1 2026 13F: $17.42B biotech portfolio, top holdings & key buys/sells. Click here to read more.",
                "category": "company",
                "datetime": 1784640414,
                "headline": "Tracking Baker Brothers Portfolio: Q1 2026 Update"
              },
              {
                "id": 140977013,
                "url": "https://finnhub.io/api/news?id=0ca787b8d9130278ed0e7cc63691221b1f3d4ac2546209e8729a89acb3a868c6",
                "image": "",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "HC Wainwright & Co.  analyst Mitchell S. Kapoor   reiterates Incyte (NASDAQ:INCY) with a Buy and maintains $140 price target.",
                "category": "company",
                "datetime": 1784615425,
                "headline": "HC Wainwright & Co. Reiterates Buy on Incyte, Maintains $140 Price Target"
              },
              {
                "id": 140961075,
                "url": "https://finnhub.io/api/news?id=cffda6abacbacb10f1ab1cfb04b69376d4da6bdf87dd29f22082c36c286acd31",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Halozyme Therapeutics (NASDAQ:HALO) has entered into a global collaboration and license agreement with Incyte (NASDAQ:INCY) to support the development of subcutaneous formulations of INCA033989, expanding the use of its ENHANZE® drug delivery technology into another partnered program. Key Investor TakeawaysHalozyme signed a global collaboration and license agreement with Incyte centered on ENHANZE® drug delivery technology.",
                "category": "company",
                "datetime": 1784559763,
                "headline": "Halozyme Signs ENHANZE Collaboration with Incyte for Subcutaneous INCA033989 Development"
              },
              {
                "id": 140958865,
                "url": "https://finnhub.io/api/news?id=fe19aee917b682379e43eb92e51267d0b966c6a7e12e193fa0f4b1239dad3666",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Halozyme Therapeutics, Inc. (Nasdaq: HALO) (\"Halozyme\" or the \"Company\") today announced that it has entered into a global collaboration and license agreement with Incyte (Nasdaq: INCY) to evaluate additional subcutaneous formulations of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs), utilizing Halozyme's proprietary ENHANZE® drug delivery technology. The collaboration will focus on",
                "category": "company",
                "datetime": 1784548800,
                "headline": "Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE® Technology"
              },
              {
                "id": 140958478,
                "url": "https://finnhub.io/api/news?id=cc6ec253511baccbdfea5ad1f5f444625c032d12536f4b0d04339169e1be0d6d",
                "image": "https://www.chartmill.com/images/uploads/Undervalued_500_264px_webp_74997b3ff2.webp",
                "source": "ChartMill",
                "related": "INCY",
                "summary": "Incyte Corp (INCY) offers a compelling value opportunity with strong profitability, near-zero debt, and a P/E of 15.76—well below the biotech industry average of 36.43. Despite slowing growth forecasts, its low valuation provides a solid margin of safety.",
                "category": "company",
                "datetime": 1784546426,
                "headline": "Incyte Corp (NASDAQ:INCY) Shows Value Stock Strength With Strong Fundamentals and Low Valuation"
              },
              {
                "id": 140965151,
                "url": "https://finnhub.io/api/news?id=6e09676ee2faf44c563ffb6d43432f0a928562e1a85e9fbc345546cf2b476777",
                "image": "",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme" or the "Company") today announced that it has entered into a global collaboration and license agreement with Incyte (NASDAQ:INCY) to evaluate",
                "category": "company",
                "datetime": 1784534503,
                "headline": "Halozyme Therapeutics Signs Agreement With Incyte To Mull Additional Subcutaneous Formulations Of INCA033989 Mutant Calreticulin-Targeted Monoclonal Antibody"
              },
              {
                "id": 140955778,
                "url": "https://finnhub.io/api/news?id=989fbbfabc0bbae37e46ab4bb57fb1e7723b8234cb8ccda6eb5366a42f05e17e",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2285994413/image_2285994413.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "INCY",
                "summary": "Xencor (XNCR) stays a Strong Buy as XmAb819 and XmAb942 advance; key data due 2026–2027 and $542M cash extends runway—read the outlook now.",
                "category": "company",
                "datetime": 1784493770,
                "headline": "Xencor: Strong Buy, XmAb819 Presentation, And End Of 2026 XmAb942 Interim Data"
              },
              {
                "id": 140934672,
                "url": "https://finnhub.io/api/news?id=87e27eb69603b6ccc7a6a57a2d4741fe9b7d8c1349d5a887b8c1f5ef9659d186",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "WILMINGTON, Del., July 17, 2026--Incyte Data to Be Highlighted in Four Rapid Oral Presentations at ESMO 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers",
                "category": "company",
                "datetime": 1784308200,
                "headline": "Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers"
              },
              {
                "id": 140935749,
                "url": "https://finnhub.io/api/news?id=bea42c5120469a8c954f17659495dd562c8902c0244836e35eb6837eb95f7ee1",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1196320934/image_1196320934.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "INCY",
                "summary": "Incyte Corporation is a profitable, cash-generating biotech with a robust pipeline and a core revenue driver in Jakafi. Read more on INCY stock here.",
                "category": "company",
                "datetime": 1784301703,
                "headline": "Incyte: Profitable Biotech That Could Be Close To Exploding"
              },
              {
                "id": 140937696,
                "url": "https://finnhub.io/api/news?id=a553b39a41af82b706247ec18aa19d8ef3e0571d48245853b03dd7a9bbf8d0b5",
                "image": "",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "Rapid oral presentations will highlight new Phase 1 data across Incyte’s solid tumor portfolioBoth INCB161734, an investigational, potent, selective and orally bioavailable KRAS G12D inhibitor, and INCA338901, a",
                "category": "company",
                "datetime": 1784293970,
                "headline": "Incyte To Present New Phase 1 Solid Tumor Data, Including KRAS G12D and TGFβR2×PD‑1 Programs, At ESMO 2026"
              },
              {
                "id": 140925108,
                "url": "https://finnhub.io/api/news?id=05939657d6c850e1eebf82da32b184016550b8b3393b7ffd86aea3de083daf7d",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1285391908/image_1285391908.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "INCY",
                "summary": "Steven Cress, Seeking Alpha's Head of Quant, provides his top 2 stocks for H2 2026.",
                "category": "company",
                "datetime": 1784220120,
                "headline": "Steven Cress' Top 2 Stocks H2 2026"
              },
              {
                "id": 140919919,
                "url": "https://finnhub.io/api/news?id=ac38e40815783f8ec5171d72b4c86aa0d5496672e10888f4bb0f5347b866864d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Get paid a guaranteed income on your Vertex shares today, which you keep no matter what, for agreeing to sell them at a higher price if the stock keeps climbing.",
                "category": "company",
                "datetime": 1784207177,
                "headline": "Collect 9.8% On VRTX Stock Now, And Still Keep 15% Of Upside"
              },
              {
                "id": 140917605,
                "url": "https://finnhub.io/api/news?id=9b0419b4f5188dcfa8be73ee7427bd5e72acdec1e9a88099cd671cf7f6b7d196",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte is scheduled to release its second-quarter results later this month, with analysts projecting a double-digit increase in its bottom line figure.",
                "category": "company",
                "datetime": 1784164726,
                "headline": "What to Expect From Incyte's Q2 2026 Earnings Report"
              },
              {
                "id": 140911616,
                "url": "https://finnhub.io/api/news?id=a21356dd71ba4a29f749ef6a9402b694ac4b5f7bec9fd511f75b6d42947c718e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 8.6% to $114.25 per share while the index has gained 8.2%.",
                "category": "company",
                "datetime": 1784133437,
                "headline": "Incyte (INCY): Buy, Sell, or Hold Post Q1 Earnings?"
              },
              {
                "id": 140902248,
                "url": "https://finnhub.io/api/news?id=40bf04d5730d9953faaebb0f7710b06678dc230e6d9574421efc3f181641f562",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2250479883/image_2250479883.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "INCY",
                "summary": "Syndax Pharma outlook: Revuforj first-mover edge, pipeline catalysts (Niktimvo), and profitability path amid misses. Click here to read more about SNDX.",
                "category": "company",
                "datetime": 1784047680,
                "headline": "A Fresh Look At Syndax Pharmaceuticals"
              },
              {
                "id": 140898821,
                "url": "https://finnhub.io/api/news?id=915e96bee8a935b573658cd266498a4469639874ea9e63198fef5e4fae5c3427",
                "image": "",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "Barclays  analyst Etzer Darout   maintains Incyte (NASDAQ:INCY) with a Overweight and raises the price target from $117 to $134.",
                "category": "company",
                "datetime": 1784012695,
                "headline": "Barclays Maintains Overweight on Incyte, Raises Price Target to $134"
              },
              {
                "id": 140890161,
                "url": "https://finnhub.io/api/news?id=e25110c78ca2177615e41497f4272b141937d60a5e1b269003abf9d7270f7d7c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Healthcare stocks were higher late Monday afternoon, with the NYSE Healthcare Index rising 0.2% and",
                "category": "company",
                "datetime": 1783971281,
                "headline": "Sector Update: Healthcare Stocks Advance Late Afternoon"
              },
              {
                "id": 140888428,
                "url": "https://finnhub.io/api/news?id=ed15eb87356bea39d17c294679a13f32dbb5cc7c416f7aa1579ca7722654403b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "For investors seeking exposure to biotechnology's future, Incyte presents a clearer forward picture of accelerating growth, while the larger Regeneron asks for more faith in its pipeline.",
                "category": "company",
                "datetime": 1783964231,
                "headline": "Own Regeneron For Biotech Growth? Incyte Is Making Its Case."
              },
              {
                "id": 140888631,
                "url": "https://finnhub.io/api/news?id=f141f5f93afa2376a17eccdb81a87ce04b3a142187092e639c75235d6edf9843",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte (INCY) is back in focus after releasing complete safety and efficacy data from a Phase 1/2 study of latarcibart, its investigational monoclonal antibody for von Willebrand disease, and advancing the program into Phase 3. See our latest analysis for Incyte. Against this backdrop, Incyte’s shares have been firming, with a 30 day share price return of 7.54% and a 90 day share price return of 19.47%, while the 1 year total shareholder return of 66.78% points to strong longer term momentum...",
                "category": "company",
                "datetime": 1783962522,
                "headline": "Incyte (INCY) Could Be 8% Overvalued As Latarcibart Moves Into Phase 3"
              },
              {
                "id": 140887161,
                "url": "https://finnhub.io/api/news?id=aed32e5440335247d1d54e1a848e0f60f7f66ffd9371a9b6a69f6d8f58de61e3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte recently reported full Phase 1/2 multidose data for latarcibart (VGA039), an investigational, once‑monthly subcutaneous monoclonal antibody that targets Protein S and showed substantial reductions in bleeding rates across all von Willebrand disease types, with a favorable safety profile, in 16 treated patients. The therapy’s potential to offer the first self‑administered, once‑monthly prophylactic option for VWD, versus frequent intravenous factor infusions, could materially change...",
                "category": "company",
                "datetime": 1783955436,
                "headline": "How Investors May Respond To Incyte (INCY) Latarcibart Data In Von Willebrand Disease Prophylaxis"
              },
              {
                "id": 140887162,
                "url": "https://finnhub.io/api/news?id=a54ac809d7cdb682cc8a30ea6b1cc5e4ce52c4dcab3da92267c40898fb12ac33",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte Corporation (NASDAQ:INCY) on Monday reported complete Phase 1/2 multidose data for latarcibart (VGA039), showing substantial reductions in bleeding episodes and a favorable safety profile in patients with von Willebrand disease (VWD). VWD is the most common inherited bleeding disorder, affecting about 1% of the population. It is caused by a deficiency or malfunction of the von Willebrand factor, a blood protein needed for platelets to clot properly. Read Also: Incyte Bets $1.25 Billion On",
                "category": "company",
                "datetime": 1783949108,
                "headline": "Incyte Says Early Data Points To Promise For Once-Monthly Preventive Treatment For Inherited Blood Disorder"
              },
              {
                "id": 140886052,
                "url": "https://finnhub.io/api/news?id=a487fe79641a5675cdde5b8921f6b47577015aee11c289601fe16b2ede882a21",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how biotechnology stocks fared in Q1, starting with Incyte (NASDAQ:INCY).",
                "category": "company",
                "datetime": 1783945839,
                "headline": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks"
              },
              {
                "id": 140887931,
                "url": "https://finnhub.io/api/news?id=e7bc2ada588cf2adac84f1c0501fa0221bd7ce5aaec251bb11ce57714a088ce5",
                "image": "https://image.cnbcfm.com/api/v1/image/108331043-1783365848624-gettyimages-2280068333-sc1_1154_pvccmh9y.jpeg?v=1783365884&w=1920&h=1080",
                "source": "CNBC",
                "related": "INCY",
                "summary": "Economy is one of the most important categories in CNBC’s annual America’s Top States for Business rankings. Several states stand out for economic strength.",
                "category": "company",
                "datetime": 1783936801,
                "headline": "The 10 best state economies in America in 2026"
              },
              {
                "id": 140887877,
                "url": "https://finnhub.io/api/news?id=cdbb5549ed0b6511090695ecb351e10424f0d4e6f46e9305e90cc729adbbc3b3",
                "image": "",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "BMO Capital  analyst Evan Seigerman   maintains Incyte (NASDAQ:INCY) with a Market Perform and raises the price target from $94 to $112.",
                "category": "company",
                "datetime": 1783933048,
                "headline": "BMO Capital Maintains Market Perform on Incyte, Raises Price Target to $112"
              },
              {
                "id": 140883892,
                "url": "https://finnhub.io/api/news?id=e514bb5e9f92d121de0f4c7a453af020ffe4125b9dd18482ef5eed90ce7c69d7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "WILMINGTON, Del., July 13, 2026--Phase 1/2 Multidose Data for VGA039 (Latarcibart) Show Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types",
                "category": "company",
                "datetime": 1783929600,
                "headline": "Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types"
              },
              {
                "id": 140856160,
                "url": "https://finnhub.io/api/news?id=f876d79aaa0f42fdd94092d76f6a95c9aa9d7384368c9d05ba671d9e973b0e50",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2195840496/image_2195840496.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "INCY",
                "summary": "Seeking Alpha's Head of Quant, Steve Cress, provides a mid-year update on his top 10 stocks for 2026.",
                "category": "company",
                "datetime": 1783622040,
                "headline": "Steven Cress' Top 10 Stocks For 2026 (Mid-Year Review)"
              },
              {
                "id": 140846990,
                "url": "https://finnhub.io/api/news?id=69f5b1271559deaac456457fd86796529813269ee230961a08b70f458add660c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte and TG Therapeutics are seeing strong share growth, backed up by booming revenue and earnings.",
                "category": "company",
                "datetime": 1783556700,
                "headline": "2 Fast-Growing Pharmaceutical Stocks to Buy Now"
              },
              {
                "id": 140843654,
                "url": "https://finnhub.io/api/news?id=9d1002029bc82808b25ccb335642eb3cc1cc4ba8647e4508fc48b73a0d083390",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1314804423/image_1314804423.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "INCY",
                "summary": "Jonathan Faison, who runs ROTY biotech community, shares why much of the current euphoria in biotech is driven by fundamentals.",
                "category": "company",
                "datetime": 1783519200,
                "headline": "Biotech Euphoria Driven By Fundamentals"
              },
              {
                "id": 140840573,
                "url": "https://finnhub.io/api/news?id=5e139a297017ff79fead3a17df77dd2984859059085fd34751ce71e2a30a986a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Get paid a guaranteed income on your Vertex shares today, which you keep no matter what, for agreeing to sell them at a higher price if the stock keeps climbing.",
                "category": "company",
                "datetime": 1783514909,
                "headline": "Collect 9.0% On VRTX Stock Now, And Still Keep 15% Of Upside"
              },
              {
                "id": 140840730,
                "url": "https://finnhub.io/api/news?id=fb64b0659f3223fcb2bf9e7a59579554e2b2943853a21329479369a2c1004907",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "WILMINGTON, Del., July 08, 2026--Incyte (Nasdaq:INCY) announced today that it has scheduled its second quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, July 28, 2026.",
                "category": "company",
                "datetime": 1783512000,
                "headline": "Incyte to Report Second Quarter Financial Results"
              },
              {
                "id": 140834756,
                "url": "https://finnhub.io/api/news?id=dc3cf7f4fad94fb261d230d6d8782221966701b25c4009d4f60cd68acc524703",
                "image": "",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "RBC Capital  analyst Brian Abrahams   maintains Incyte (NASDAQ:INCY) with a Sector Perform and raises the price target from $95 to $99.",
                "category": "company",
                "datetime": 1783424452,
                "headline": "RBC Capital Maintains Sector Perform on Incyte, Raises Price Target to $99"
              },
              {
                "id": 140820207,
                "url": "https://finnhub.io/api/news?id=e634c63449847296def19e3be997568b9cd97e012a951028aaa2e51f1a651d48",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "WILMINGTON, Del., July 06, 2026--Incyte Completes Acquisition of Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio",
                "category": "company",
                "datetime": 1783341540,
                "headline": "Incyte Completes Acquisition of Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio"
              },
              {
                "id": 140803373,
                "url": "https://finnhub.io/api/news?id=04fa362e5a6f6419113b59c3ec42755bd692320fa5f07823c28d34a88007bf46",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Three outlier inflow signals push biopharmaceutical firm Incyte Corporation (INCY) up 71% in a year.",
                "category": "company",
                "datetime": 1783094315,
                "headline": "Incyte Shares Rise on EPS Growth, Lifted Guidance, Expansion"
              },
              {
                "id": 140799700,
                "url": "https://finnhub.io/api/news?id=9c6075678d469eee278d70ae35d9032c473b5da23c2c1d1b8d783ef525594bf8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract significant competition, spanning from industry behemoths with seemingly infinite resources to small, nimble players with chips on their shoulders.",
                "category": "company",
                "datetime": 1783083006,
                "headline": "1 Mid-Cap Stock to Research Further and 2 We Avoid"
              },
              {
                "id": 140789500,
                "url": "https://finnhub.io/api/news?id=76b4c71462ddf1de0eb8dc5b797b4a8614571f81d8290645852d7fa11e604573",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2271204950/image_2271204950.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "INCY",
                "summary": "SA Quant's Top Stocks for 2026 are delivering exceptional gains, crushing the S&P 500 in the face of volatility and uncertainty.",
                "category": "company",
                "datetime": 1782975600,
                "headline": "Top 10 Quant Stocks Of 2026 Up Nearly 70%"
              },
              {
                "id": 140784865,
                "url": "https://finnhub.io/api/news?id=4270f0cd6534569bb58db6869e1381a5d9d863bc2d0e6b1ad89b65e79ad902b0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte Corporation (NASDAQ:INCY) is one of billionaire Cliff Asness’ top 10 healthcare stock picks. On June 22, Truist Securities analyst Srikripa Devarakonda raised the price target on Incyte Corporation (NASDAQ:INCY) from $103 to $105, while keeping a Hold rating on the stock. Devarakonda said the target increase was partly driven by a one-time financial boost […]",
                "category": "company",
                "datetime": 1782941476,
                "headline": "Incyte (INCY): Truist Raises the Price Target to $105 as a Government Settlement Adds $246 Million to Net Sales"
              },
              {
                "id": 140765608,
                "url": "https://finnhub.io/api/news?id=fefbd33e7cfd5d86f08520d8ef428b365d018a64f3eb4788cc3912935ee81c0b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte shares hit a 52-week high as Opzelura gains regulatory momentum, pipeline advances and a CMS settlement boosts investor sentiment.",
                "category": "company",
                "datetime": 1782754740,
                "headline": "INCY Stock Hits 52-Week High on Regulatory Updates for Opzelura"
              },
              {
                "id": 140762789,
                "url": "https://finnhub.io/api/news?id=dff0729a53d86028bcaad627f4f79f8728e025ee987cb90e7289e1e6755a33ce",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte (INCY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.",
                "category": "company",
                "datetime": 1782741240,
                "headline": "Incyte (INCY) Surges 5.8%: Is This an Indication of Further Gains?"
              },
              {
                "id": 140760986,
                "url": "https://finnhub.io/api/news?id=865bad36696b74053c7f2391f7042582376a529dd0e6f80fbe2ee18add45ad11",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.",
                "category": "company",
                "datetime": 1782727815,
                "headline": "1 Cash-Producing Stock with Solid Fundamentals and 2 We Turn Down"
              },
              {
                "id": 140760509,
                "url": "https://finnhub.io/api/news?id=337ac098885636449238758e63c48f4fad5c91798a779231f37aa746dc0a730c",
                "image": "https://www.chartmill.com/images/uploads/THUMBNAILS_CHARTMILL_1000_528_39_9880df21cf.webp",
                "source": "ChartMill",
                "related": "INCY",
                "summary": "The week closed with the Strait of Hormuz still bleeding headlines and crude already down nine percent. Sunday, Washington and Tehran said they were standing down and heading to Doha. Whether that holds is anyone's guess, but for one trading day, at least, the market gets to price the calmer outcome.",
                "category": "company",
                "datetime": 1782726305,
                "headline": "Hormuz Goes Quiet, Software Wakes Up, and Burry Picks a Side"
              },
              {
                "id": 140761145,
                "url": "https://finnhub.io/api/news?id=2e8307f45b0c2e02a5fc5e231dd592c5aefb8aebb9dc12e251e7af44aa09f8d4",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2194222153/image_2194222153.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "INCY",
                "summary": "Incyte's valuation still appears attractive if pipeline execution continues and analysts eventually raise long-term expectations. Learn why INCY stock is a buy.",
                "category": "company",
                "datetime": 1782722154,
                "headline": "Incyte: New Catalysts Support Another Leg Higher"
              },
              {
                "id": 140746362,
                "url": "https://finnhub.io/api/news?id=866f94055d957539f4eec4b59ee2d919ce3be9e4d57f48bccc490bcef31b9c5f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "If you are wondering whether Incyte stock still offers value after a strong run, this article breaks down what the current price might be implying about the company. Incyte closed at US$113.75, with returns of 15.8% over 7 days, 16.9% over 30 days, 12.2% year to date, 66.4% over 1 year, 82.7% over 3 years, and 36.1% over 5 years. This raises fair questions about how much of the story is already reflected in the share price. Recent coverage of Incyte has focused on how the stock has re rated...",
                "category": "company",
                "datetime": 1782572852,
                "headline": "Incyte (INCY) Stock After 66% One-Year Rally Is The Market Too Optimistic Now"
              },
              {
                "id": 140744461,
                "url": "https://finnhub.io/api/news?id=f95e68ffa413d9ed079cc8ee6d0f89f6d411efa6cd8b56a6584e69b97e9b41b5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte (NasdaqGS: INCY) reported a favorable CHMP opinion for Opzelura in Europe for atopic dermatitis. The company released pivotal Phase 2 data for zilurgisertib in ultra rare fibrodysplasia ossificans progressiva. Phase 1 results for INCA033989 in mutCALR mutant myeloproliferative neoplasms showed strong clinical activity. Phase 3 frontMIND data for tafasitamab in first-line aggressive lymphomas indicated robust efficacy outcomes. For investors tracking Incyte, these updates highlight...",
                "category": "company",
                "datetime": 1782540409,
                "headline": "Incyte (INCY) Wins EU Backing For Opzelura As Pipeline Data Builds Across Four Drugs"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 0,
            "positive_hits": 4,
            "recomputed_at_score": true,
            "sentiment_score_raw": 1.2,
            "source_article_count": 53,
            "discarded_article_count": 37
          },
          "sentimentPoints": 6
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 23.3,
        "grade": "良好",
        "items": {
          "bbPoints": 3,
          "adxPoints": 3,
          "sarPoints": 2.4000000000000004,
          "vcpPoints": 2.9,
          "macdPoints": 2.4,
          "vcpPayload": {
            "vcp_pass": true,
            "vcp_score": 2.9,
            "vcp_reason": "波幅收縮(19.8%→7.6%)；量縮(v10/v30=0.78)；站上MA50；升放量(近10日2日)；Ready=Y；Confirm=Y",
            "vcp_metrics": {
              "up_days": 7,
              "vol_ref": 1840510,
              "down_days": 2,
              "vcp_ready": true,
              "above_ma50": true,
              "avg_vol_10": 1426920,
              "avg_vol_20": 1679510,
              "avg_vol_30": 1840510,
              "range_pct_10": 0.07601749075008402,
              "range_pct_20": 0.08509922637066927,
              "range_pct_30": 0.19769596367305747,
              "up_expand_ok": true,
              "lookback_used": 59,
              "near_20d_high": true,
              "contraction_ok": true,
              "down_shrink_ok": false,
              "up_expand_days": 2,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 0.7752851111920066,
              "dist_to_20d_high": 0.005685618729096929,
              "down_shrink_days": 2,
              "breakout_level_20d": 119.6,
              "vcp_breakout_confirm": true,
              "contraction_ratio_10_30": 0.3845171612901467
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": true
          },
          "kdjAdxPoints": 0.8,
          "rsiKdjPoints": 3.2,
          "volumeWeight": 2,
          "maCrossPoints": 1.6,
          "shortRsiPoints": 1,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 1,
          "volumePointsTechnical": 1.6
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "一般",
        "items": {
          "position": {
            "score": 1.6,
            "details": {
              "atrPct": 2.6989572822065253,
              "turnoverUsdM": 508.89506952,
              "liquidityPoints": 0.6,
              "volatilityPoints": 1
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.INCY",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 112.5008,
            "strength_details": {
              "ma_score": 1.5,
              "atr_score": 2,
              "rsi_score": 2,
              "macd_score": 1.5,
              "volume_score": 3
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1.3,
            "stop_loss_percent": 5.4,
            "take_profit_price": 126.9493,
            "target_multiplier": 1.9,
            "technical_strength": 1.98,
            "take_profit_percent": 6.8
          },
          "positionPoints": 1.6,
          "stopLossPoints": 1.8,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2597457627118644,
          "stopLossPercent": 5.397914564413051,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [
    {
      "code": "VIX_MISSING",
      "symbol": "US.INCY",
      "message": "VIX market context is required for market environment scoring",
      "missing": [
        "VIX"
      ],
      "provider": "scoring"
    }
  ],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": false,
    "missingFields": [
      "VIX"
    ],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 92.86,
    "atr": {
      "atr": 3.2096,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 6,
      "atr_pct": 2.7
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "超買或超賣風險",
      "score": 2,
      "value": 149.14
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "平衡",
      "score": 4,
      "value": 0.0121
    },
    "kdj": {
      "d": 68.53,
      "j": 84.3,
      "k": 73.79,
      "rule": "Cursor_18.24 K/D cross",
      "score": 6,
      "signal": "強金叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "入貨中",
      "score": 8,
      "value": 61.2
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 10,
      "trend": "強流入",
      "value": 18887206,
      "recentSlope": 1125580.6,
      "previousSlope": 55400
    },
    "rsi": 52.5,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 8,
      "trend": "上升",
      "value": 115.3352,
      "position": "SAR喺價下",
      "distancePct": 3.01,
      "previousTrend": "上升"
    },
    "ma50": 106.8182,
    "macd": {
      "macd": 2.9489196557951516,
      "trend": "中性偏多",
      "signal": 3.307974855347816,
      "histogram": -0.3590551995526643
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 10,
      "value": 116.4547,
      "position": "連續5日>VWAP",
      "consecutiveAbove": 25
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "量價配合",
      "ratio": 2.51,
      "score": 8,
      "avgVolume": 1703730,
      "currentVolume": 4279306
    },
    "derived": {
      "ma20": 116.253,
      "ma50": 106.8182,
      "prevClose": 117.67,
      "avgVolume10": 1706751,
      "avgVolume20": 1703730,
      "changePercent": 1.06,
      "avgVolumeForScore": 1703730
    },
    "ma_cross": {
      "ma20": 116.253,
      "ma50": 106.8182,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "多頭",
      "score": 4,
      "prevMa20": 115.9945,
      "prevMa50": 106.4162,
      "spreadPct": 8.83,
      "isVolumeBreakout": true
    },
    "bollinger": {
      "lower": 113.1903,
      "upper": 119.3157,
      "position": "上半部"
    },
    "rsi_short": 60.35,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 2.51
    }
  }
}

{
  "close": 118.92,
  "volume": 4279306,
  "changePercent": 1.06
}